We also expect pivotal data for our C5 antibody siRNA combination in generalized myasthenia gravis. Finally ... Now to cash flow and the balance sheet. Regeneron generated approximately $3.7 ...

We have full flexibility, a strong balance sheet, and also an improving return ... we also are now taking Fabhalta into myasthenia gravis to give another option for those patients, and as I ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

UCB, a global biopharmaceutical company, today announced the CHMP (Committee for Medicinal Products for Human Use) has issued a positive opinion for the self-administration of RYSTIGGO® ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.

Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hopes will shake up the ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Google has told the European Union (EU) it will not comply with its new fact-checking law, according to a new report saying the massive search engine will not incorporate the measures into its ...

Review and Outlook: Meta CEO Mark Zuckerberg and Chief Global Affairs Officer Joel Kaplan address the company’s decision to abandon its censorship regime, by walking back most of the platform ...

If you would like to create a fact sheet for your unit, school, department or program, refer to the following resources and contact your senior communicator. Please note: the school sample below is ...